AACR 101st Annual Meeting 2010: Meet-the-Expert Sessions

Advances in Imaging Immune Responses In Vivo
Michael Dustin, New York University Cancer Institute, New York, NY

Cell Adhesion and Signaling Pathways Regulating Brain Tumor Angiogenesis
Joseph H. McCarty, UT M. D. Anderson Cancer Center, Houston, TX

Cell Plasticity in Metastasis
Lynne-Marie Postovit, University of Western Ontario, London, ON, Canada

Chemical Synthesis of Natural Products in Oncology Lead Discoveries
Samuel J. Danishefsky, Memorial Sloan-Kettering Cancer Center, New York, NY

DCIS: Prediction of Future Disease
Peggy L. Porter, Fred Hutchinson Cancer Research Center, Seattle, WA

Lymphatics and Lymphoid Chemokines in Tumor Immunity
Melody A. Swartz, École Polytechnique Fédérale de Lausanne, Lausanne, Switzerland

Mononuclear Phagocyte Response in Cancer: Analysis in Context
Mikael J. Pittet, Massachusetts General Hospital, Charlestown, MA

Nonsteroidal Anti-inflammatory Drugs: Chemoprevention, Cancer Therapy, and Biomarker Development
Andrew J. Dannenberg, Cornell University Weill Medical College, New York, NY

Pharmacogenetic and Epidemiological Studies in Cooperative Group Trials
Christine B. Ambrosone, Roswell Park Cancer Institute, Buffalo, NY

Systematic Identification of Cancer Genes Using RNAi
David E. Root, The Broad Institute of MIT and Harvard, Cambridge, MA

The Promise and Limitations of Kinase Inhibitors
Neil P. Shah, UCSF Comprehensive Cancer Center, San Francisco, CA

Visualizing Cells and Viruses at Molecular Resolution with 3-D Electron Microscopy
Sriram Subramaniam, National Cancer Institute, Bethesda, MD

Adoptive Immunotherapy of Cancer
Steven A. Rosenberg, National Cancer Institute, Bethesda, MD

Clinical Trial Design for Basic Scientists
Emily Bergsland, UCSF Helen Diller Comprehensive Cancer Center, San Francisco, CA

Combining Adoptive Cell Therapy and Nanoparticle Drug Delivery for Enhanced Cancer Immunotherapy: Using Antigen-Specific “Pharmacytes” to Target Nanoparticles to Tumors
Darrell J. Irvine, MIT Koch Institute for Integrative Cancer Research, Cambridge, MA

Exploiting and Antagonizing microRNA for Therapeutic Applications
Luigi Naldini, San Raffaele Scientific Institute, Milano, Italy

Functional Breast Cancer Genomics
Joe W. Gray, Lawrence Berkeley National Laboratory, Berkeley, CA

How Do Cancer Cells Deal With Stress: A Systems Approach
Lawrence J. Marnett, Vanderbilt University Medical Center, Nashville, TN

Protein Tyrosine Phosphatases in Human Cancer
Benjamin G. Neel, University of Toronto Ontario Cancer Institute, Toronto, ON, Canada

Reducing Attrition and Enhancing Efficiency in Cancer Drug Development
James H. Doroshow, National Cancer Institute, Bethesda, MD

Regulation of Glutathione and Glutathione S-transferases by Transcription Factor Nrf2
John D. Hayes, University of Dundee, Dundee, United Kingdom

Targeting Myc for Cancer Therapy
Gerard I. Evan, UCSF Comprehensive Cancer Center, San Francisco, CA

Targeting Signaling Pathways and Molecular Alterations in Breast Cancer
Nancy E. Hynes, Friedrich Miescher Institute, Basel, Switzerland

TNF Alpha and Cancer
Frances R. Balkwill, Barts & the London School of Medicine & Dentistry, London, United Kingdom

Childhood and Adolescence Exposures as Determinants of Lifetime Cancer Risk
Graham A. Colditz, Washington University School of Medicine, St. Louis, MO

Costimulation of Tumor Immunity
Lieping Chen, Johns Hopkins University School of Medicine, Baltimore, MD

Emerging Targets in Cancer: Development of Hedgehog Pathway Inhibitors
Frederic J. De Sauvage, Genentech, Inc., South San Francisco, CA

Hormones and Risk and Prevention of Breast, Endometrial, and Ovarian Cancer
Malcolm C. Pike, USC/Norris Comprehensive Cancer Center, Los Angeles, CA

Magnetic Resonance Metabolic and Physiological Imaging of Cancer
Sarah J. Nelson, University of California, San Francisco, CA

Mechanobiology and Tumor Progression
Valerie M. Weaver, University of California, San Francisco, CA

New Kidney Cancer Strategies Emerging from Studies of the VHL Tumor Suppressor Protein
William G. Kaelin Jr., Dana-Farber Cancer Institute, Boston, MA

Personalized Oncology Medicine: Towards Biologically Driven Clinical Decision Making in Oncology
David R. Parkinson, Nodality, South San Francisco, CA

RNAi: From Discovery to Use in the Clinic
Mark E. Davis, California Institute of Technology, Pasadena, CA

Combining Pathology and Genetics in Breast Cancer
Marc J. Van de Vijver, Netherlands Cancer Institute, Amsterdam, The Netherlands

DNA Methylation as Biomarkers for Screening and Early Detection of Cancer
James G. Herman, Johns Hopkins University School of Medicine, Baltimore, MD

Genetically Engineered Mouse Models for Preclinical Research
Cory Abate-Shen, Columbia University Irving Comprehensive Cancer Center, New York, NY

Genomic Strategies for Achieving Personalized Cancer Treatment
Joseph R. Nevins, Duke University Medical Center, Durham, NC

Regulating p53 Expression through Mdm2 and Mdmx
Carol L. Prives, Columbia University, New York, NY

Regulatory Network Modeling
Chris Sander, Memorial Sloan-Kettering Cancer Center, New York, NY

RNAi: New Promise in Cancer Therapy
Anastasia Khvorova, RXi Pharmaceuticals, Worcester, MA

Spending Some Real Time with Caspase-2: A Putative Tumor Suppressor
Douglas R. Green, St. Jude Children's Research Hospital, Memphis, TN

Stat3: A Central Signaling Node for Tumor Immune Evasion
Drew M. Pardoll, Johns Hopkins Kimmel Comprehensive Cancer Center, Baltimore, MD

Tumor Microenvironment in Cancer Progression and Metastasis
Raghu Kalluri, Beth Israel Deaconess Medical Center, Boston, MA

Bidirectional Translational Research Approach to Accelerate Development of Effective Cancer Immunotherapeutics
Thomas F. Gajewski, University of Chicago, Chicago, IL

Differentiation and Functions of Mononuclear Phagocytes
Frederic Geissmann, Universite Rene Descartes Paris V, Paris, France

Endogenous DNA Damage: Biomarker Facts and Fallacies
Peter C. Dedon, Massachusetts Institute of Technology, Cambridge, MA

Genetic Predisposition to Breast Cancer and their Clinical Applications
Nazneen Rahman, Institute of Cancer Research, Sutton, United Kingdom

Mass Spectrometry Approaches for Discovery and Verification of Cancer Biomarkers
Susan J. Fisher, University of California, San Francisco, CA

Next-Generation Preventive HPV Vaccines
Richard B. Roden, Johns Hopkins University, Baltimore, MD

Oncogene Addiction and Therapeutic Opportunities in Human Cancer
Jeffrey Settleman, Massachusetts General Hospital, Charlestown, MA

Pharmacogenetics of Tamoxifen Therapy
Vered Stearns, Johns Hopkins Kimmel Comprehensive Cancer Center, Baltimore, MD

Systems Biology Approach to Personalized Medicine
Gordon B. Mills, UT M. D. Anderson Cancer Center, Houston, TX

The ATM-p53 Pathway: From Molecular Mechanisms To Clinical Interventions
Michael B. Kastan, St. Jude Children's Research Hospital, Memphis, TN

Germline Genetic Variation and the Clinical Course of Disease After a Diagnosis of Cancer
Paul D. P. Pharoah, University of Cambridge, Cambridge, United Kingdom

Long-term Outcomes in Adult Survivors of Childhood Cancer: A Model for Cancer Survivorship Research
Leslie L. Robison, St. Jude Children's Research Hospital, Memphis, TN

Lymphoid Malignancies
A. Thomas Look, Dana-Farber Cancer Institute, Boston, MA

Role of Postpartum Involution in the Promotion of Pregnancy-Associated Breast Cancer
Pepper Jo Schedin, University of Colorado Health Sciences Center, Aurora, CO

Th17 Cells in Cancer: Friends or Foes?
Weiping Zou, University of Michigan Medical School, Ann Arbor, MI

The Nuts and Bolts of p53 Action
Laura D. Attardi, Stanford University School of Medicine, Stanford, CA